Esther Rajavelu Biography and Net Worth

President and Chief Executive Officer of Spero Therapeutics

Esther Rajavelu is the President and Chief Executive Officer at Spero Therapeutics. She also serves as a member on Spero’s Board of Directors.

Ms. Rajavelu has more than two decades of life sciences sector experience combining equities research, investment banking, and strategy consulting. Prior to joining Spero, she was the CFO at Fulcrum Therapeutics, a clinical stage biopharmaceutical company, focused on rare genetic diseases. Ms. Rajavelu previously enjoyed a successful Wall Street career, serving as a senior equities research analyst, covering SMID-cap biotechnology companies at UBS, Oppenheimer, and Deutsche Bank. She was also a healthcare investment banker at Bank of America Merrill Lynch and EY Capital Advisors.

Ms. Rajavelu holds an MBA in Finance and Health Care Management from The Wharton School at the University of Pennsylvania, and a BA from Wesleyan University.

What is Esther Rajavelu's net worth?: The estimated net worth of Esther Rajavelu is at least $1.13 million as of May 4th, 2026. Ms. Rajavelu owns 986,851 shares of Spero Therapeutics stock worth more than $1,125,010 as of September 22nd. This net worth approximation does not reflect any other assets that Ms. Rajavelu may own. Learn More about Esther Rajavelu's net worth.
How do I contact Esther Rajavelu?: The corporate mailing address for Ms. Rajavelu and other Spero Therapeutics executives is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. Spero Therapeutics can also be reached via phone at (857) 242-1600 and via email at [email protected]. Learn More on Esther Rajavelu's contact information.
Has Esther Rajavelu been buying or selling shares of Spero Therapeutics?: Esther Rajavelu has not been actively trading shares of Spero Therapeutics in the last ninety days. Most recently, Esther Rajavelu sold 25,240 shares of the business's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $2.51, for a transaction totalling $63,352.40. Following the completion of the sale, the insider now directly owns 986,851 shares of the company's stock, valued at $2,476,996.01. Learn More on Esther Rajavelu's trading history.
Who are Spero Therapeutics' active insiders?: Spero Therapeutics' insider roster includes Ankit Mahadevia (CEO), and Esther Rajavelu (President and Chief Executive Officer). Learn More on Spero Therapeutics' active insiders.
Are insiders buying or selling shares of Spero Therapeutics?: During the last year, insiders at the sold shares 4 times. They sold a total of 171,869 shares worth more than $406,848.82. The most recent insider tranaction occured on May, 4th when insider Esther Rajavelu sold 25,240 shares worth more than $63,352.40. Insiders at Spero Therapeutics own 2.9% of the company. Learn More about insider trades at Spero Therapeutics.
Information on this page was last updated on 5/4/2026.

Esther Rajavelu Insider Trading History at Spero Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/4/2026	Sell	25,240	$2.51	$63,352.40	986,851
2/6/2026	Sell	87,917	$2.36	$207,484.12	1,012,091
2/2/2026	Sell	18,442	$2.20	$40,572.40	1,100,008
11/7/2025	Sell	40,270	$2.37	$95,439.90	869,450
2/5/2025	Sell	20,689	$0.78	$16,137.42	724,720

Esther Rajavelu Buying and Selling Activity at Spero Therapeutics

Spero Therapeutics Company Overview

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $1.35

$1.28

$1.35

50 Day Range

MA: $1.24

$1.11

$1.70

2 Week Range

Now: $1.35

$1.08

$3.08

Volume

1,187,191 shs

Average Volume

804,789 shs

Market Capitalization

$78.86 million

P/E Ratio

12.23

Dividend Yield

N/A

Beta

1.49